BGI Units Lose Appeal Over Illumina DNA Sequencing IP

By Bonnie Eslinger (December 17, 2021, 3:41 PM GMT) -- The Court of Appeal on Friday rejected a bid by BGI Group subsidiaries to overturn findings that they infringed valid patents for rapid DNA sequencing held by Illumina Cambridge Ltd., holding the inventions were not obvious in light of prior research in the field.

The patents claim inventions in the field of DNA sequencing, specifically a technique known as "sequencing by synthesis." Three of the four patents at issue are for modified nucleotides.

The BGI companies — Latvia MGI Tech SIA, MGI Tech Co. Ltd., MGI International Sales Co. Ltd. and MGI Tech Hong Kong Co. Ltd., formerly BGI Complete Genomics...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!